Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Open accessThe DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Abstract
: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [3]
In the citing paper
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophrenia60.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [60]
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Existing drugs are poorly tolerated and exhibit little differences in efficacy (Lieberman et al., 2005).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Based upon the emerging pharmacology of the NMDAR, Javitt and Zukin (1991) proposed that the psychotomimetic effects of PCP were due to blockade of the NMDA receptors.”
BackgroundTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundLesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248 · cited 1×
“We focused on glutamatergic signal transduction before there was any evidence that it could be relevant to neuropsychiatric disorders (Coyle and Schwarcz, 1976).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun.319:1281–1286. [DOI] [PubMed] [Google Scholar] · DOI
Cited by
Items 201–300 of 954
Castañé, A., Santana, N., & Artigas, F. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3946-6 · Cited by 84
“NMDA-R hypofunction hypothesis stemmed from the clinical observation that subanesthetic doses of noncompetitive NMDA-R antagonists such as phencyclidine (PCP) and ketamine induced psychotic reactions in healthy individuals and exacerbated the symptomatology in schizophrenic patients (Coyle 2006; Javitt and Zukin 1991;…”
Gao, W., Yang, S.-S., Mack, N. R., & Chamberlin, L. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01196-w · Cited by 80
Ohi, K., Hashimoto, R., Ikeda, M., Yamamori, H., Yasuda, Y., Fujimoto, M., Umeda‐Yano, S., Fukunaga, M., Fujino, H., Watanabe, Y., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu171 · Cited by 79
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Coyle, J. T., Balu, D., Benneyworth, M., Basu, A., & Roseman, A. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jcoyle · Cited by 74
Self-citationContribution of hippocampal region CA3 to consciousness and schizophrenic hallucinations
Behrendt, R. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.12.009 · Cited by 78
“NMDA-receptor hypofunction resulting from genetic abnormalities has been implicated in the pathophysiology of schizophrenia (Coyle, 2006; Lisman et al., 2008).”
Timofeeva, O. A., & Levin, E. D. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.038 · Cited by 74
“Bergeron R, Coyle JT, Tsai G, Greene RW (2005) NAAG reduces”
BackgroundIon channels in EEG: isolating channel dysfunction in NMDA receptor antibody encephalitis
Symmonds, M., Moran, C. H., Leite, M. I., Buckley, C., Irani, S. R., Stephan, K. E., Friston, K. J., & Moran, R. J. (2018) · Brain · doi:10.1093/brain/awy107 · Cited by 77
“…direct NMDAR hypofunction in inhibitory interneurons leads to disinhibition in corticolimbic regions, underpinning symptoms in schizophrenia (Olney et al., 1999; Benes and Berretta, 2001; Lewis et al., 2004; Woo and Crowell, 2005; Coyle, 2006; Homayoun and Moghaddam, 2007; Nakazawa et al., 2012).”
BackgroundPasquini, S., Contri, C., Merighi, S., Gessi, S., Borea, P. A., Varani, K., & Vincenzi, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031219 · Cited by 77
“Adenosine is also involved in glutamatergic and dopaminergic modulation [24].”
BackgroundMetabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia
Dogra, S., & Conn, P. J. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.121.000460 · Cited by 79
“Accumulating evidence suggests that dysfunction of glutamatergic signaling may contribute to the pathogenesis of schizophrenia (Coyle, 2006; Moghaddam and Javitt, 2012; Hu et al., 2015; Stahl, 2018).”
BackgroundHahn, C.-G., Banerjee, A., MacDonald, M. L., Cho, D.-S., Kamins, J., Nie, Z., Borgmann-Winter, K. E., Grosser, T., Pizarro, A., Ciccimaro, E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005251 · Cited by 76
“The PSD contains molecular machineries for NMDA, AMPA and mGlu receptors, all of which have been implicated in the pathophysiology of various neuropsychiatric illnesses [40,41,42,43].”
Optogenetic Insights into Social Behavior Function
Yizhar, O. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.029 · Cited by 81
Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex
Beggiato, S., Tanganelli, S., Fuxé, K., Antonelli, T., Schwarcz, R. M., & Ferraro, L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.019 · Cited by 79
Brandt, A. S., Unschuld, P. G., Pradhan, S., Lim, I. A. L., Churchill, G., Harris, A. D., Hua, J., Barker, P. B., Ross, C. A., van Zijl, P. C. M., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.017 · Cited by 78
Berridge, M. J. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00188.2017 · Cited by 81
Glycine transporters and synaptic function
Zafra, F., & Giménez, C. (2008) · IUBMB Life · doi:10.1002/iub.128 · Cited by 73
“The main evidence for NMDAR hypofunction came from observations that phencyclidine and ketamine, open channel blockers of NMDARs, induce symptoms of schizophrenia in healthy humans and precipitate psychotic episodes in schizophrenic patients (62).”
BackgroundLabrie, V., Clapcote, S. J., & Roder, J. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.09.016 · Cited by 81
“Research has indicated that NMDAR hypofunction is involved in the biological mechanism of schizophrenia, and suggests that enhanced NMDAR activity may be therapeutic (Coyle, 2006; Javitt, 2004).”
BackgroundMutant Mouse Models: Genotype-Phenotype Relationships to Negative Symptoms in Schizophrenia
O’Tuathaigh, C. M. P., Kirby, B. P., Moran, P. M., & Waddington, J. L. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp125 · Cited by 77
Adams, W. K., Kusljic, S., & van den Buuse, M. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.035 · Cited by 76
Delille, H. K., Mezler, M., & Marek, G. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.005 · Cited by 76
“…following acute administration of N-methyl-D-aspartate (NMDA) channel blocking antagonists, (2) effects of glycine B receptor agonist on negative symptoms of schizophrenia, and (3) prominent schizophrenia risk genes affecting NMDA receptor function or glutamatergic neurotransmission (Coyle, 2006).”
BackgroundEmerging drugs for schizophrenia
Agid, O., Kapur, S., & Remington, G. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.479 · Cited by 65
“These same drugs have been shown to induce relapse of psychotic symptoms in previously stabilized patients with schizophrenia [86] , and unmedicated patients with schizophrenia were found to be more sensitive than normal volunteers to the effects of NMDA antagonists [87] .”
BackgroundHasan, A., Falkai, P., & Wobrock, T. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320030012 · Cited by 74
Xi, D., Keeler, B., Zhang, W., Houle, J. D., & Gao, W.-J. (2009) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.09.013 · Cited by 66
Endogenous 24 S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices
Sun, M.-Y., Izumi, Y., Benz, A., Zorumski, C. F., & Mennerick, S. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00890.2015 · Cited by 64
“Interestingly, NMDAR hypofunction is linked to psychotic symptoms associated with schizophrenia (Coyle 2006; Coyle et al. 2010; Tamminga 1998).”
BackgroundSydnor, V. J., & Roalf, D. R. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.06.028 · Cited by 67
Myelin copper and the cuprizone model of schizophrenia
Konradi, C. (2011) · Frontiers in Bioscience · doi:10.2741/s129 · Cited by 66
“Abnormalities in the glutamate system have been indicated in schizophrenia, leading to the ‘glutamate hypothesis’ of schizophrenia (107, 108).”
BackgroundEffects of Chronic D-Serine Elevation on Animal Models of Depression and Anxiety-Related Behavior
Otte, D.-M., Barcena de Arellano, M. L., Bilkei-Gorzo, A., Albayram, Ö., Imbeault, S., Jeung, H., Alferink, J., & Zimmer, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067131 · Cited by 68
“thus a tight regulation of D-serine levels may be important [29,30].”
BackgroundKulikova, S. P., Tolmacheva, E. A., Anderson, P., Gaudias, J., Adams, B. E. L., Zheng, T. W., & Pinault, D. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08263.x · Cited by 70
“A postulated mechanism of these impairments is the reduced N-methyl-D-aspartate receptor (NMDAr) function at glutamatergic synapses on GABAergic interneurons (Coyle, 2006; Moghaddam & Jackson, 2003; Rolls et al., 2008).”
BackgroundProof-of-concept randomized controlled trial of pregnenolone in schizophrenia
Marx, C. E., Lee, J., Subramaniam, M., Rapisarda, A., Bautista, D., Chan, E. S., Kilts, J. D., Buchanan, R. W., Eu, P. W., Verma, S. K., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3673-4 · Cited by 73
Mice with genetically altered glutamate receptors as models of schizophrenia: A comprehensive review
Inta, D., Monyer, H., Sprengel, R., Meyer‐Lindenberg, A., & Gass, P. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.010 · Cited by 69
“Several hypotheses have been proposed to explain the pathophysiological changes in schizophrenia (Seeman, 1987; Coyle, 2006).”
BackgroundA computational neuroscience approach to schizophrenia and its onset
Rolls, E. T., & Deco, G. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.09.001 · Cited by 113
Presynaptic NMDA Receptor Mechanisms for Enhancing Spontaneous Neurotransmitter Release
Kunz, P. A., Roberts, A. C., & Philpot, B. D. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2482-12.2013 · Cited by 65
“Not surprisingly, NMDAR dysfunction has been implicated in a number of neurological disorders, including schizophrenia, Alzheimer’s disease, epilepsy, ethanol toxicity, pain, depression, and certain neurodevelopmental disorders (Rice and DeLorenzo, 1998; Cull-Candy et al., 2001; Sze et al., 2001; Mueller and Meador-Wo…”
BackgroundKlug, M., Hill, R. A., Choy, K. H. C., Kyrios, M., Hannan, A. J., & van den Buuse, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.015 · Cited by 67
Cognition-Emotion Dysinteraction in Schizophrenia
Anticevic, A., & Corlett, P. R. (2012) · Frontiers in Psychology · doi:10.3389/fpsyg.2012.00392 · Cited by 62
“or the egg debate as to which one of these disruptions may be the proximal cause of downstream symptoms (Coyle, 2006), yet considering these complex interactions will be vital as we move toward a more complete understanding of this illness.”
BackgroundSapkota, K., Mao, Z., Synowicki, P., Lieber, D., Liu, M., Ikezu, T., Gautam, V., & Monaghan, D. T. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230391 · Cited by 70
“Discussion Evidence from a variety of genetic, biochemical, and pharmacologic studies support the concept that NMDAR hypofunction contributes to many of the diverse symptoms of schizophrenia (Coyle, 2006; Lisman et al., 2008; Kantrowitz and Javitt, 2010).”
Banerjee, A., Wang, H.-Y., Borgmann-Winter, K. E., MacDonald, M. L., Kaprielian, H., Stucky, A., Kvasic, J., Egbujo, C., Ray, R., Talbot, K., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.115 · Cited by 66
Wierońska, J. M., Stachowicz, K., Acher, F., Lech, T., & Pilc, A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2502-2 · Cited by 65
“effects observed after MK-801 administration (Carlsson et al. 2001; Coyle 2006; Dall’Olio et al. 2000; Lindsley et al. 2006).”
Kraeuter, A.-K., Mashavave, T., Suvarna, A., van den Buuse, M., & Sarnyai, Z. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05467-2 · Cited by 66
“The NMDA receptor hypofunction model is based on clinical evidence suggesting dysfunctional glutamatergic neurotransmission in schizophrenia (Coyle 2006; van den Buuse 2010; Coyle et al. 2012).”
BackgroundThe Role of Akt-GSK-3β Signaling and Synaptic Strength in Phencyclidine-Induced Neurodegeneration
Lei, G., Xia, Y., & Johnson, K. M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301511 · Cited by 74
“It is well known that acute administration of NMDA antagonists can induce a broad range of antipsychoticsensitive, schizophrenia-like symptomatology in both humans and rodents, findings that have greatly contributed to a hypoglutamatergic hypothesis of schizophrenia (Farber et al, 1995; Olney and Farber, 1995; Jentsch…”
BackgroundPreclinical Behavioral Models for Predicting Antipsychotic Activity
Castagné, V., Moser, P. C., & Porsolt, R. D. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57010-4 · Cited by 64
The phenotype of recurrent 10q22q23 deletions and duplications
van Bon, B. W. M., Balciuniene, J., Fruhman, G., Nagamani, S. C. S., Broome, D. L., Cameron, E., Martinet, D., Roulet, E., Jacquemont, S., Beckmann, J. S., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.211 · Cited by 71
Hirota, T., & Kishi, T. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.06.038 · Cited by 64
“In schizophrenia, its pathophysiology is currently based on the hypothesis of dopaminergic hyperfunction and glutamatergic hypofunction (Goff and Coyle, 2001; Coyle, 2006).”
BackgroundSpellmann, I., Rujescu, D., Musil, R., Mayr, A. J., Giegling, I., Genius, J., Zill, P., Dehning, S., Opgen-Rhein, M., Cerovecki, A., et al. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.06.004 · Cited by 67
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?
Stone, J. M. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311400779 · Cited by 81
“…changes might be related to a primary dopaminergic abnormality [Olney and Farber, 1995], whereas others have suggested that abnormalities in glutamate transmission or NMDA receptor function could drive changes in dopamine [Stone et al. 2007; Coyle, 2006; Harrison and Weinberger, 2005].”
BackgroundmicroRNAs Sculpt Neuronal Communication in a Tight Balance That Is Lost in Neurological Disease
Thomas, K. T., Gross, C., & Bassell, G. J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00455 · Cited by 64
“Most of these deficits have been attributed to dysregulation of NMDA receptors (Coyle, 2006), and the NMDA receptor hypofunction hypothesis of schizophrenia originally arose from the observation that NMDA receptor antagonists, e.g., PCP and ketamine, mimic the positive and negative symptoms of…”
BackgroundAttractor cortical neurodynamics, schizophrenia, and depression
Rolls, E. T. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01333-7 · Cited by 114
Transport mechanism and pharmacology of the human GlyT1
Wei, Y., Li, R., Meng, Y., Hu, T., Zhao, J. L., Gao, Y., Bai, Q., Li, N., & Zhao, Y. (2024) · Cell · doi:10.1016/j.cell.2024.02.026 · Cited by 63
Inhibitors of GlyT1 Affect Glycine Transport via Discrete Binding Sites
Mezler, M., Hornberger, W., Mueller, R., Schmidt, M. U., Amberg, W., Braje, W. M., Ochse, M., Schoemaker, H., & Behl, B. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.049312 · Cited by 63
“Hypofunction of NMDAR is thought to be implicated in schizophrenia (Millan, 2005; Coyle, 2006).”
BackgroundOrphan GPCRs and Neuromodulation
Civelli, O. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.009 · Cited by 60
“Other newer neuromodulator systems, such as the metabotropic glutamate system, are taking stand (Coyle, 2006; Stone et al., 2007; Moghaddam and Javitt, 2012; Raedler et al., 2007) but orphan GPCR systems may also play a role.”
Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus
Gono, T., Kawaguchi, Y., Kaneko, H., Nishimura, K., Hanaoka, M., Kataoka, S., Okamoto, Y., Katsumata, Y., & Yamanaka, H. (2011) · Rheumatology · doi:10.1093/rheumatology/keq408 · Cited by 63
Schizophrenia: Treatment Targets Beyond Monoamine Systems
Ibrahim, H. M., & Tamminga, C. A. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105851 · Cited by 64
Horiguchi, M., Huang, M., & Meltzer, H. Y. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2251-2 · Cited by 66
“Cortical hypodopaminergic, as well as hypoglutamatergic activity, have been postulated to be major causes of the cognitive impairment of schizophrenia (Goldman-Rakic and Selemon 1997; Coyle 2006).”
BackgroundNagai, T., Kirihara, K., Tada, M., Koshiyama, D., Koike, S., Suga, M., Araki, T., Hashimoto, K., & Kasai, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-02267-1 · Cited by 62
Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates
Vita, A., Minelli, A., Barlati, S., Deste, G., Giacopuzzi, E., Valsecchi, P., Turrina, C., & Gennarelli, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00402 · Cited by 68
“Based on the N-Methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia (Coyle, 2006; Frontiers in Pharmacology | www.frontiersin.org 8 April 2019 | Volume 10 | Article 402 Moghaddam and Javitt, 2012), the setting of pharmacological agents that enhance NMDAR function could…”
MethodA quantitative meta-analysis of brain glutamate metabolites in aging
Roalf, D. R., Sydnor, V. J., Woods, M. M., Wolk, D. A., Scott, J. C., Reddy, R. D., & Moberg, P. J. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.07.015 · Cited by 64
“Among the biological mechanisms proposed to contribute to such integrity loss, alterations in brain glutamate (Glu) are considered critical, given Glu’s ubiquity and involvement in cellular energetics and high-order cognitive functions (Coyle, 2006; Curtis and Johnston, 1974; Erecińska et al., 1990; McEntee and Crook,…”
BackgroundBarnes, S. A., Young, J. W., & Neill, J. C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.024 · Cited by 61
“…NMDA receptor(s) and/or abnormal downstream NMDA receptor effects being core to the pathophysiology of the disease (Olney and Faber, 1995; Olney et al. 1999; Goff and Coyle, 2001), potentially providing a more compelling model than the hyperdopaminergic hypothesis of schizophrenia (Coyle, 2006).”
BackgroundIwata, Y., Nakajima, S., Plitman, E., Mihashi, Y., Caravaggio, F., Chung, J. K., Kim, J., Gerretsen, P., Mimura, M., Remington, G. J., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.016 · Cited by 64
“Glutamatergic and GABAergic neurometabolites are of particular interest, given that hypofunctioning N-methyl D-aspartate (NMDA) receptors on GABAergic neurons as well as abnormal glutamatergic and GABAergic neurotransmission are implicated in the pathophysiology of schizophrenia (Coyle, 2006).”
Disruption of Conscious Access in Schizophrenia
Berkovitch, L., Dehaene, S., & Gaillard, R. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2017.08.006 · Cited by 60
Li, J., Zhu, L., Guan, F., Yan, Z., Liu, D., Han, W., & Chen, T. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.09.005 · Cited by 62
A Role for Oxytocin in the Etiology and Treatment of Schizophrenia
Rich, M. E., & Caldwell, H. K. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00090 · Cited by 55
“In addition to the dopamine hypothesis, there is the glutamate hypothesis, which supposes that it is the hypofunctioning of N-methyl-D-aspartate (NMDA) receptors that contribute to the negative symptoms and cognitive impairments associated with schizophrenia (19).”
BackgroundArco, A. D., Segovia, G., & Mora, F. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1288-3 · Cited by 67
Conscious Experience and Episodic Memory: Hippocampus at the Crossroads
Behrendt, R. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2013.00304 · Cited by 65
“In patients with schizophrenia, reduced NMDA-receptor function is a consequence of genetic abnormalities, while, in healthy subjects, NMDA-receptor dysfunction can be brought about temporarily by ingestion of NMDA-receptor antagonists (reviewed in Coyle, 2006; Lisman et al., 2008).”
BackgroundHorisawa, T., Nishikawa, H., Toma, S., Ikeda, A., Horiguchi, M., Ono, M., Ishiyama, T., & Taiji, M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.01.026 · Cited by 59
Impaired D-Serine-Mediated Cotransmission Mediates Cognitive Dysfunction in Epilepsy
Klatte, K., Kirschstein, T., Otte, D. M., Pothmann, L., Müller, L., Tokay, T., Kober, M., Uebachs, M., Zimmer, A., & Beck, H. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5423-12.2013 · Cited by 61
Bronson, S. L., Ahlbrand, R., Horn, P. S., Kern, J. R., & Richtand, N. M. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.12.040 · Cited by 56
Zorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
“Why ketamine? The seminal studies of Krystal and colleagues (9) were designed to test the hypothesis that hypofunction of NMDARs is involved in the pathophysiology of schizophrenia and other psychotic disorders (37, 53).”
BackgroundFunctional ‘glial’ GLYT1 glycine transporters expressed in neurons
Raiteri, L., & Raiteri, M. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06802.x · Cited by 60
An integrated network model of psychotic symptoms
Looijestijn, J., Blom, J. D., Aleman, A., Hoek, H. W., & Goekoop, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.016 · Cited by 55
Mice mutant for genes associated with schizophrenia: Common phenotype or distinct endophenotypes?
Desbonnet, L., Waddington, J. L., & O’Tuathaigh, C. M. P. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.001 · Cited by 63
Mutant models for genes associated with schizophrenia
Desbonnet, L., Waddington, J. L., & O'Tuathaigh, C. M. P. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370308 · Cited by 56
Talbot, K., Ong, W., Blake, D. J., Tang, J., Louneva, N., Carlson, G. C., & Arnold, S. E. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_5 · Cited by 69
Olszewski, R. T., Wegorzewska, M. M., Monteiro, A. C., Krolikowski, K. A., Zhou, J., Kozikowski, A. P., Long, K. D., Mastropaolo, J. P., Deutsch, S. I., & Neale, J. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.016 · Cited by 57
Wible, C. G. (2012) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2012.00180 · Cited by 56
Genetic loss of D‐amino acid oxidase activity reverses schizophrenia‐like phenotypes in mice
Labrie, V., Wang, W., Barger, S. W., Baker, G. B., & Roder, J. C. (2010) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2009.00529.x · Cited by 55
“tered in conjunction with conventional antipsychotics (Coyle 2006; Heresco-Levy et al. 2005; Tsai et al. 1998).”
BackgroundPathway Analyses Implicate Glial Cells in Schizophrenia
Duncan, L. E., Holmans, P., Lee, P. H., O'Dushlaine, C. T., Kirby, A. W., Smoller, J. W., Öngür, D., & Cohen, B. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089441 · Cited by 61
“This role, its effects on cell growth and its toxic properties, have all led to proposals that abnormalities of glutamate underlie psychotic and mood disorders (For reviews of the evidence cited here [21–24]).”
BackgroundElevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia
O’Connor, J. A., & Hemby, S. E. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.09.022 · Cited by 58
“Substantial evidence indicates a hypofunction of NMDA (see for review (Coyle, 2006)) and AMPA receptors in the brains of individuals diagnosed with schizophrenia (Goff and Coyle, 2001; Goff et al., 2001; Lynch, 2004; O’Neill et al., 2004).”
BackgroundBadcock, J. C., & Hugdahl, K. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00180 · Cited by 53
“A glutamate hypothesis behind some of the pathophysiology seen in schizophrenia is not new (see Coyle, 2006—where abnormal functioning of glutamate receptors, and the interaction with GABA receptor inter-neurons, has been suggested to be involved in the pathophysiology of schizophrenia, and…”
BackgroundNeurosteroids in Schizophrenia: Pathogenic and Therapeutic Implications
Cai, H., Cao, T., Zhou, X., & Yao, J. K. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00073 · Cited by 55
“Thus, hypofunction of the N-methyl-d-aspartate (NMDA) type glutamate receptor, possibly on critical GABAergic interneurons, may also contribute to the pathophysiology beyond dopaminergic dysfunction of SZ (26).”
BackgroundPanizzutti, R., Fisher, M., Garrett, C. T., Man, W. H., Sena, W., Madeira, C., & Vinogradov, S. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.04.011 · Cited by 57
Thalman, C., Horta, G., Qiao, L., Endle, H., Tegeder, I., Cheng, H., Laube, G., Sigurdsson, T., Hauser, M. J., Tenzer, S., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0053-1 · Cited by 51
Interneuron development and dysfunction
Yang, J., Yang, X. W., & Tang, K. (2021) · FEBS Journal · doi:10.1111/febs.15872 · Cited by 60
Kōyama, Y. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00261 · Cited by 54
“Riluzole Increases in L-Glu transport Depression Banasr et al. (2010)”
BackgroundThe Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
Egerton, A., & M. Stone, J. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784961 · Cited by 49
“[173] Coyle, J.”
BackgroundStojković, T., Radonjić, N. V., Velimirović, M., Jevtić, G., POPOVIC, V. M., Doknić, M., & Petronijević, N. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.013 · Cited by 58
“These findings, along with other evidence of glutamatergic neuronal dysfunction in schizophrenia (Coyle, 2006), have contributed to the development of PCP animal models of schizophrenia (Olney et al., 1999), suitable for research into pathological mechanisms of this disease and evaluation of novel…”
BackgroundPrefrontal Cortex Glutamate Correlates with Mental Perspective-Taking
Montag, C., Schubert, F., Heinz, A., & Gallinat, J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003890 · Cited by 58
“Glutamatergic dysfunction has been suggested in various disorders marked by specific alterations of social reciprocity, like autism [9,10] and schizophrenia [11], with research on the genetic underpinnings of these conditions currently focusing on the glutamatergic system [12,11].”
BackgroundImprovement of cognitive function in schizophrenia withN-acetylcysteine: A theoretical review
Yolland, C. O. B., Phillipou, A., Castle, D. J., Neill, E., Hughes, M. E., Galletly, C. A., Smith, Z. M., Francis, P. S., Dean, O. M., Sarris, J. J., et al. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1478766 · Cited by 56
Schizophrenia, Not a Psychotic Disorder: Bleuler Revisited
Loch, A. A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00328 · Cited by 61
Kelly, D. L., Raley, H., Lo, S., Wright, K., Liu, F., McMahon, R. P., Moolchan, E. T., Feldman, S. M., Richardson, C. M., Wehring, H. J., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq124 · Cited by 59
“with schizophrenia, and agents targeting both nicotinic and NMDA receptors may show promise for improving cognitive deficits present in many people with this illness.(16,17) Thus, evidence suggests that nicotinic modulation plays a role in reasons for smoking in schizophrenia patients ie potentially different from rea…”
BackgroundPredictably irrational: assaying cognitive inflexibility in mouse models of schizophrenia
Brigman, J. L. (2010) · Frontiers in Neuroscience · doi:10.3389/neuro.01.013.2010 · Cited by 52
“EFFECTS OF SUBCHRONIC PCP TREATMENT ON DISCRIMINATION AND REVERSAL There is compelling evidence implicating the glutamate system in the pathophysiology of schizophrenia (Coyle, 2006).”
BackgroundLányi, O., Koleszár, B., Wenning, A. S., Balogh, D., Engh, M. A., Horvath, A. A., Fehérvári, P., Hegyi, P., Molnár, Z., Unoka, Z., et al. (2024) · Schizophrenia · doi:10.1038/s41537-024-00476-y · Cited by 55
“An increasing body of evidence supports the role of γ -amino butyric acid (GABA) and glutamate in the pathophysiology of schizophrenia 4,5 , highlighting a disrupted cortical excitation-inhibition (E/I) imbalance as a neurobiological characteristic of the disorder 6 .”
BackgroundMöhler, H., Boison, D., Singer, P., Feldon, J., Pauly-Evers, M., & Yee, B. K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.003 · Cited by 53
“The resulting dysregulation in neuronal network activity may contribute to the pathophysiology of schizophrenia [15,16].”
BackgroundA Population-Specific Uncommon Variant in GRIN3A Associated with Schizophrenia
Takata, A., Iwayama, Y., Fukuo, Y., Ikeda, M., Okochi, T., Maekawa, M., Toyota, T., Yamada, K., Hattori, E., Ohnishi, T., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.024 · Cited by 50
Huang, M., Li, Z., Dai, J., Shahid, M., Wong, E. H. F., & Meltzer, H. Y. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.20 · Cited by 54
“contribute to their ability to improve cognitive impairment in schizophrenia (Konradi and Heckers, 2003; Coyle, 2006).”
BackgroundDe Novo Truncating Mutation in Kinesin 17 Associated with Schizophrenia
Tarabeux, J., Champagne, N., Brustein, E., Hamdan, F. F., Gauthier, J., Lapointe, M., Maios, C., Piton, A., Spiegelman, D., Henrion, É., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.018 · Cited by 56
Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
Jiraskova-Vanickova, J., Ettrich, R., Vorlova, B., E. Hoffman, H., Lepsik, M., Jansa, P., & Konvalinka, J. (2011) · Current Drug Targets · doi:10.2174/138945011795677755 · Cited by 52
Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era
Marino, M. J., Knutsen, L. J. S., & Williams, M. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701094q · Cited by 56
Curley, A. A., Eggan, S. M., Lazarus, M. S., Huang, Z. J., Volk, D. W., & Lewis, D. A. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.018 · Cited by 51
“occur in schizophrenia (Coyle, 2006), has been associated with”
BackgroundDopaminergic Circuitry and Risk/Reward Decision Making: Implications for Schizophrenia
Stopper, C. M., & Floresco, S. B. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu165 · Cited by 51
Chen, J., Calhoun, V. D., Pearlson, G. D., Perrone‐Bizzozero, N. I., Sui, J., Turner, J. A., Bustillo, J., Ehrlich, S., Sponheim, S. R., Cañive, J. M., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.073 · Cited by 53
“…signaling: (SLC1A1, GRM4, GNG2): Glutamate receptor signaling plays a crucial role in neurocognitive processes and aberrant glutamate neurotransmission may be associated with positive and negative symptoms as well as cognitive deficits in SZ (Coyle, 2006; Egan et al., 2004; Krystal et al., 2010).”
BackgroundSystems Biology, Bioinformatics, and Biomarkers in Neuropsychiatry
Alawieh, A. M., Zaraket, F. A., Li, J., Mondello, S., Nokkari, A., Razafsha, M., Fadlallah, B. H., Boustany, R., & Kobeissy, F. H. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00187 · Cited by 57
“…and Garrison, 1983; See-man, 1987; Baumeister and Francis, 2002), (4) the glutamate hypothesis that associates SZ with hyperglutaminergic signaling (Coyle, 2006; Stahl, 2007; Egerton and Stone, 2012; Moghad-dam and Javitt, 2012), and (5) the revised dopamine hypothesis that includes both…”
BackgroundSuchanek, R., Owczarek, A., Paul-Samojedny, M., Kowalczyk, M., Kucia, K., & Kowalski, J. (2013) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.11100234 · Cited by 51
“Alterations of GABA or dopamine neurotransmission may contribute to psychopathological symptoms of schizophrenia.(20,21) The PANSS scale is the most widely used to measure”
Metadata
- Authors
- Coyle, J. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Coyle, Joseph T.
- ORCID
- Coyle, Joseph T.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2006-06-14
- Volume
- 26
- Issue
- 4-6
- Pages
- 363-382
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11881825
- OpenAlex
- W2008639041
- Cited by
- 917
- References
- 159
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 16 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 35 · 2019: 47 · 2018: 43 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 47 · 2013: 74 · 2012: 62
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH060450, MH P50-60450, MH R01-572901)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, glutamate, NMDA receptor, dopamine hypothesis, negative symptoms, cognitive impairment, NMDA receptor antagonists, schizophrenia risk genes, GABAergic interneurons, antipsychotic drugs, glutamatergic neurotransmission
- MeSH terms
- Animals, Dopamine, Glutamates, Humans, Models, Biological, Synaptic Transmission, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.